BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8273368)

  • 1. [Interferon-alpha in cutaneous T-cell lymphoma].
    Knobler R
    Wien Med Wochenschr; 1993; 143(16-17):435-7. PubMed ID: 8273368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
    Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
    Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of cutaneous T-cell lymphomas].
    Rappersberger K; Ortel B; Forstinger C; Wolff K
    Wien Klin Wochenschr; 1994; 106(10):300-8. PubMed ID: 8053197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma.
    Herrmann JJ; Roenigk HH; Hönigsmann H
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):1077-88. PubMed ID: 8522485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
    Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
    Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interferon-alpha therapy in non-Hodgkin's lymphoma].
    Fridrik MA
    Wien Med Wochenschr; 1993; 143(16-17):429-34. PubMed ID: 8273367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution.
    Suchin KR; Cucchiara AJ; Gottleib SL; Wolfe JT; DeNardo BJ; Macey WH; Bromley PG; Vittorio CC; Rook AH
    Arch Dermatol; 2002 Aug; 138(8):1054-60. PubMed ID: 12164743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon in the treatment of cutaneous T-cell lymphoma.
    Olsen EA
    Dermatol Ther; 2003; 16(4):311-21. PubMed ID: 14686974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing clinical outcomes in cutaneous T-cell lymphoma.
    Zackheim HS; Koh HK; Weinstock MA
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):1021-9. PubMed ID: 8522482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.
    Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH
    J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas.
    Dréno B
    Stem Cells; 1993 Jul; 11(4):269-75. PubMed ID: 8401250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids.
    Knobler RM; Trautinger F; Radaszkiewicz T; Kokoschka EM; Micksche M
    J Am Acad Dermatol; 1991 Feb; 24(2 Pt 1):247-52. PubMed ID: 2007670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photopheresis for cutaneous T cell lymphoma.
    Heald PW
    Ann N Y Acad Sci; 1991 Dec; 636():171-7. PubMed ID: 1793207
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
    Ferenczi K; Yawalkar N; Jones D; Kupper TS
    Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination therapy with interferon alfa 2a and PUVA in cutaneous T-cell lymphoma].
    Otte HG; Herges A; Stadler R
    Hautarzt; 1992 Nov; 43(11):695-9. PubMed ID: 1468931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal combination with PUVA: rationale and clinical trial update.
    Stadler R
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
    Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
    J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.